PURPOSE: Childhood cancer survivors are at risk for late effects which may be managed pharmacologically. The purposes of this study were to estimate and compare the prevalence of psychoactive medication use of adult survivors of childhood cancer and sibling controls, identify predictors of medication use in survivors, and investigate associations between psychoactive medications and health-related quality of life (HRQOL). METHODS: Psychoactive medication use from 1994 to 2010 was evaluated in 10,378 adult survivors from the Childhood Cancer Survivor Study. A randomly selected subset of 3,206 siblings served as a comparison group. Multivariable logistic regression models were used to calculate odds ratios (OR) for baseline and new onset of self-reported psychoactive medication use and HRQOL. RESULTS: Survivors were significantly more likely to report baseline (22 vs. 15 %, p < 0.001) and new onset (31 vs. 25 %, p < 0.001) psychoactive medication use compared to siblings, as well as use of multiple medications (p < 0.001). In multivariable models, controlling for pain and psychological distress, female survivors were significantly more likely to report baseline and new onset use of antidepressants (OR = 2.66, 95 % CI = 2.01-3.52; OR = 2.02, 95 % CI = 1.72-2.38, respectively) and multiple medications (OR = 1.80, 95 % CI = 1.48-2.19; OR = 1.77, 95 % CI = 1.48-2.13, respectively). Non-cranial radiation and amputation predicted incident use of analgesics >15 years following diagnosis. Antidepressants were associated with impairment across all domains of HRQOL, with the exception of physical function. CONCLUSIONS: Prevalence of psychoactive medication use was higher among survivors for most medication classes, as was the use of multiple medications. Clinicians should be aware of the possible contribution of psychoactive medications to HRQOL. IMPLICATIONS FOR CANCER SURVIVORS: Survivors of childhood cancer are more likely to be prescribed psychoactive medication than their sibling counterparts, though use of such medication does not appear to normalize quality of life. Survivors are encouraged to consider additional interventions, including psychosocial support and physical exercise.
PURPOSE:Childhood cancer survivors are at risk for late effects which may be managed pharmacologically. The purposes of this study were to estimate and compare the prevalence of psychoactive medication use of adult survivors of childhood cancer and sibling controls, identify predictors of medication use in survivors, and investigate associations between psychoactive medications and health-related quality of life (HRQOL). METHODS: Psychoactive medication use from 1994 to 2010 was evaluated in 10,378 adult survivors from the Childhood Cancer Survivor Study. A randomly selected subset of 3,206 siblings served as a comparison group. Multivariable logistic regression models were used to calculate odds ratios (OR) for baseline and new onset of self-reported psychoactive medication use and HRQOL. RESULTS: Survivors were significantly more likely to report baseline (22 vs. 15 %, p < 0.001) and new onset (31 vs. 25 %, p < 0.001) psychoactive medication use compared to siblings, as well as use of multiple medications (p < 0.001). In multivariable models, controlling for pain and psychological distress, female survivors were significantly more likely to report baseline and new onset use of antidepressants (OR = 2.66, 95 % CI = 2.01-3.52; OR = 2.02, 95 % CI = 1.72-2.38, respectively) and multiple medications (OR = 1.80, 95 % CI = 1.48-2.19; OR = 1.77, 95 % CI = 1.48-2.13, respectively). Non-cranial radiation and amputation predicted incident use of analgesics >15 years following diagnosis. Antidepressants were associated with impairment across all domains of HRQOL, with the exception of physical function. CONCLUSIONS: Prevalence of psychoactive medication use was higher among survivors for most medication classes, as was the use of multiple medications. Clinicians should be aware of the possible contribution of psychoactive medications to HRQOL. IMPLICATIONS FOR CANCER SURVIVORS: Survivors of childhood cancer are more likely to be prescribed psychoactive medication than their sibling counterparts, though use of such medication does not appear to normalize quality of life. Survivors are encouraged to consider additional interventions, including psychosocial support and physical exercise.
Authors: Cornelia A J Brouwer; Aleida Postma; Judith M Vonk; Nynke Zwart; Maarten P van den Berg; Margreet Th E Bink-Boelkens; Wil V Dolsma; Andries J Smit; Elisabeth G E de Vries; W J E Tissing; Jourik A Gietema Journal: Eur J Cancer Date: 2011-06-21 Impact factor: 9.162
Authors: D B Greenberg; A Goorin; M C Gebhardt; L Gupta; N Stier; D Harmon; H Mankin Journal: Oncology (Williston Park) Date: 1994-11 Impact factor: 2.990
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Deborah B Crom; Zhenghong Li; Tara M Brinkman; Melissa M Hudson; Gregory T Armstrong; Joseph Neglia; Kirsten K Ness Journal: J Pediatr Oncol Nurs Date: 2014-07-15 Impact factor: 1.636
Authors: Tara M Brinkman; Chenghong Li; Kathryn Vannatta; Jordan G Marchak; Jin-Shei Lai; Pinki K Prasad; Cara Kimberg; Stefanie Vuotto; Chongzhi Di; Deokumar Srivastava; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: Emily Crochet; Vida L Tyc; Mingjuan Wang; Deo Kumar Srivastava; Kristi Van Sickle; Paul C Nathan; Wendy Leisenring; Todd M Gibson; Gregory T Armstrong; Kevin Krull Journal: J Cancer Surviv Date: 2019-11-05 Impact factor: 4.442
Authors: Andrew B Smitherman; Danielle Mohabir; Tania M Wilkins; Julie Blatt; Hazel B Nichols; Stacie B Dusetzina Journal: J Pediatr Date: 2018-02-12 Impact factor: 4.406
Authors: Tara M Brinkman; Nan Zhang; Nicole J Ullrich; Pim Brouwers; Daniel M Green; Deo Kumar Srivastava; Lonnie K Zeltzer; Marilyn Stovall; Leslie L Robison; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: E Anne Lown; Farya Phillips; Lisa A Schwartz; Abby R Rosenberg; Barbara Jones Journal: Pediatr Blood Cancer Date: 2015-12 Impact factor: 3.167
Authors: Kristen J Stefanski; Julia S Anixt; Pamela Goodman; Katherine Bowers; Wendy Leisenring; K Scott Baker; Karen Burns; Rebecca Howell; Stella Davies; Leslie L Robison; Gregory T Armstrong; Kevin R Krull; Christopher Recklitis Journal: J Natl Cancer Inst Date: 2021-04-06 Impact factor: 13.506
Authors: Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: CA Cancer J Clin Date: 2018-01-29 Impact factor: 508.702